BidaskClub cut shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a hold rating to a sell rating in a research report released on Saturday.

Several other equities analysts also recently weighed in on the company. Zacks Investment Research raised Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, March 21st. Needham & Company LLC downgraded Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, February 23rd. JPMorgan Chase downgraded Lexicon Pharmaceuticals from a neutral rating to an underweight rating and dropped their price objective for the company from $15.00 to $10.00 in a research note on Wednesday, February 14th. Finally, ValuEngine downgraded Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, February 2nd. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $24.50.

How to Become a New Pot Stock Millionaire

NASDAQ LXRX opened at $8.28 on Friday. Lexicon Pharmaceuticals has a 1-year low of $7.80 and a 1-year high of $18.00. The company has a market capitalization of $854.24, a P/E ratio of -6.52 and a beta of 0.40. The company has a quick ratio of 2.58, a current ratio of 2.59 and a debt-to-equity ratio of 4.44.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 143.31% and a negative net margin of 142.86%. The firm had revenue of $33.05 million during the quarter, compared to the consensus estimate of $29.84 million. During the same period last year, the business posted ($0.31) EPS. Lexicon Pharmaceuticals’s quarterly revenue was up 43.7% on a year-over-year basis. equities research analysts expect that Lexicon Pharmaceuticals will post -1.39 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in LXRX. Jump Trading LLC purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $104,000. Two Sigma Advisers LP purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $104,000. Quantitative Systematic Strategies LLC purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $117,000. Aperio Group LLC purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $127,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Lexicon Pharmaceuticals during the third quarter worth $149,000.

ILLEGAL ACTIVITY WARNING: “BidaskClub Lowers Lexicon Pharmaceuticals (LXRX) to Sell” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/04/17/bidaskclub-lowers-lexicon-pharmaceuticals-lxrx-to-sell.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.